Grifols (MEX:GRFP N) Cyclically Adjusted Revenue per Share: MXN135.11 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GRFP N Grifols SA MEX:GRFP N
86 GF Score
Price MXN126.63
GF Value MXN136.82
! 7 Warning Signs
View Full Analysis

What is Grifols Cyclically Adjusted Revenue per Share?

Grifols MEX:GRFP N 86 Cyclically Adjusted Revenue per Share is MXN135.11 as of Jun. 2026. GuruFocus rates MEX:GRFP N with a GF Score™ of 86/100 and a GF Value™ of MXN136.82. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Grifols's adjusted revenue per share for the three months ended in Jun. 2026 was MXN55.353. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN135.11 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Grifols's average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Grifols was 10.80% per year. The lowest was 8.80% per year. And the median was 10.20% per year.

As of today (2026-09-06), Grifols's current stock price is MXN126.63. Grifols's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN135.11. Grifols's Cyclically Adjusted PS Ratio of today is 0.94.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Grifols was 6.43. The lowest was 0.91. And the median was 1.65.


Grifols  (MEX:GRFP N) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Grifols's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=126.63/135.11
=0.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Grifols was 6.43. The lowest was 0.91. And the median was 1.65.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Grifols Cyclically Adjusted Revenue per Share Related Terms


Grifols Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Grifols's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols Cyclically Adjusted Revenue per Share Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 102.95 80.39 116.69 108.64

Grifols Quarterly Data
Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.28 91.95 108.64 132.34 135.11

MEX:GRFP N vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Grifols's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Grifols's Cyclically Adjusted PS Ratio falls into.


MEX:GRFP N
86GF Score
Grifols SA MEX:GRFP N
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Grifols's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=55.353/131.3300*131.3300
=55.353

Current CPI (Jun. 2026) = 131.3300.

Grifols Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201509 26.293 99.559 34.684
201512 28.701 100.268 37.592
201603 26.418 98.638 35.174
201606 29.638 100.333 38.794
201609 32.173 99.737 42.364
201612 34.976 101.842 45.103
201703 31.291 100.896 40.729
201706 33.523 101.848 43.227
201709 32.657 101.524 42.245
201712 36.326 102.975 46.329
201803 33.517 102.122 43.103
201806 37.294 104.165 47.020
201809 36.782 103.818 46.529
201812 38.868 104.193 48.991
201903 37.688 103.488 47.828
201906 39.840 104.612 50.015
201909 41.773 103.905 52.799
201912 41.227 105.015 51.558
202003 48.980 103.469 62.169
202006 56.446 104.254 71.105
202009 51.174 103.521 64.921
202012 45.928 104.456 57.744
202103 42.192 104.857 52.844
202106 47.374 107.102 58.091
202112 0.000 111.298 0.000
202206 48.330 118.044 53.769
202209 45.209 117.221 50.650
202212 52.140 117.650 58.203
202306 48.570 120.278 53.033
202309 43.731 121.343 47.330
202312 48.235 121.300 52.224
202406 48.312 124.409 51.000
202409 57.653 123.121 61.497
202412 63.403 124.753 66.745
202503 58.055 125.531 60.737
202506 60.418 127.251 62.355
202509 59.020 126.840 61.109
202512 61.391 128.400 62.792
202603 52.074 129.860 52.663
202606 55.353 131.330 55.353

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN135.11 mean?
Grifols (MEX:GRFP N) has a Cyclically Adjusted Revenue per Share of MXN135.11 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Grifols and its competitors.
Is Grifols' Cyclically Adjusted Revenue per Share too high?
Grifols' current Cyclically Adjusted Revenue per Share is MXN135.11. Overall, Grifols has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Grifols' Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Grifols' Cyclically Adjusted Revenue per Share of MXN135.11 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Grifols and its competitors. Grifols's current Cyclically Adjusted Revenue per Share is MXN135.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Grifols (MEX:GRFP N) has a current Cyclically Adjusted Revenue per Share of MXN135.11. The stock's GF Value™ is MXN136.82, compared to a current price of MXN126.63 — trading 7.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN135.11. Grifols' overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Grifols (MEX:GRFP N), the current Cyclically Adjusted Revenue per Share is MXN135.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (MEX:GRFP N) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of MXN126.63 is trading 7.4% below its estimated GF Value™ of MXN136.82.

Key valuation signals for MEX:GRFP N:

  • Cyclically Adjusted Revenue per Share: MXN135.11
  • GF Value™: MXN136.82 vs. price of MXN126.63 (7.4% below fair value)
  • GF Score™: 86/100 with 7 warning signs

No single metric tells the full story. See the MEX:GRFP N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
86GF Score

Get the complete analysis for MEX:GRFP N

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN126.63
Price
MXN136.82
GF Value